CHICAGO (Diya TV) — A new experimental drug from Revolution Medicines has delivered one of the most promising results ever seen in advanced pancreatic cancer, offering fresh hope for patients battling one of the deadliest forms of the disease.
Researchers presented the findings Sunday at the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The late-stage clinical trial showed that the company’s oral drug, daraxonrasib, nearly doubled survival for patients with previously treated metastatic pancreatic cancer. The results drew a standing ovation from doctors and cancer experts attending the conference. Many described the findings as a breakthrough in pancreatic cancer treatment.
The Phase 3 study enrolled about 500 patients whose cancers were driven by RAS mutations. These genetic mutations appear in more than 90% of pancreatic cancer cases and play a key role in tumor growth. Patients who received daraxonrasib lived for a median of 13.2 months. In comparison, patients who received standard chemotherapy survived for a median of 6.7 months.
The study also found that patients taking daraxonrasib experienced fewer side effects than those receiving chemotherapy. Researchers said the treatment helped patients maintain a better quality of life while extending survival. The findings mark a significant step forward for pancreatic cancer research. The disease remains one of the most difficult cancers to treat and often carries a poor prognosis.
The reaction from the oncology community highlighted the importance of the trial results. Mark A. Goldsmith, chief executive officer and chairman of Revolution Medicines, said the drug established a new benchmark for patient survival.
“These striking results firmly support daraxonrasib as the new standard of care for patients with previously treated metastatic pancreatic cancer and usher in a new era of RAS-targeted therapy for patients living with this disease,” Goldsmith said.
According to the company, no previous Phase 3 pancreatic cancer study has reported a survival improvement of this magnitude, regardless of when patients received treatment during their disease journey. The standing ovation at ASCO reflected the excitement among specialists who have spent years searching for more effective pancreatic cancer therapies.
RAS mutations are among the most common genetic changes found in cancer. Scientists have long considered these mutations difficult to target with drugs. Daraxonrasib belongs to a new class of targeted cancer therapies designed to block RAS-driven tumor growth. By focusing on the underlying genetic driver of the disease, the drug aims to slow cancer progression more effectively than traditional chemotherapy. Experts believe the success of daraxonrasib could open the door for additional RAS-targeted treatments in the future. The results also demonstrate the growing role of precision medicine, which matches treatments to specific genetic features of a patient’s cancer.
Wall Street analysts responded positively to the study results. Cory Kasimov, an analyst at Evercore, said the reaction from cancer specialists left little doubt about the drug’s potential impact. He described Daraxonrasib as a possible “historic oncology launch” and suggested that market expectations may still underestimate the treatment’s commercial opportunity. The strong survival data could position the drug as a leading option for patients with advanced pancreatic cancer if regulators approve it.
Revolution Medicines plans to submit the clinical trial data to the U.S. Food and Drug Administration through a fast-track approval pathway. The company said the review process could take as little as two months. The FDA has also authorized an expanded access program, allowing eligible patients to receive the treatment before formal approval. If approved, daraxonrasib could quickly become an important new treatment option for people with metastatic pancreatic cancer. For patients and families facing this aggressive disease, the latest findings represent a rare piece of encouraging news. Researchers and doctors now hope the breakthrough will lead to longer survival and improved quality of life for thousands of patients worldwide.
